fda warning letters compounded semaglutide tirzepatide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Beyond the Headlines: FDA Warning

PlexusDx maps 14 distinct metabolic pathways across 49 peptides and 150+ genetic insights, moving beyond one-size-fits-all dosing

Complementary approaches that may provide additional benefit include pelvic floor physical therapy for associated muscle dysfunction, psychological support for chronic pain management, and lifestyle modifications including regular exercise and anti-inflammatory dietary patterns

Published in the journal The Lancet Diabetes and Endocrinology online March 5, the study was designed to clarify the value and safety of the drugs

learn more by reading the medication guides for Xenical and Alli

Berberine is a bioactive alkaloid found in plants like goldenseal, Oregon grape, and barberry root

Explore the pros and cons of GLP-1 drugs in managing diabetes and obesity, balancing benefits like weight loss against side effects and costs